Interleukin-22 is a negative regulator of the allergic response

Cytokine

Volumn 50, Issue 2, 2010, Pages 220-227

  Schnyder, Bruno ^a   Lima, Carla ^b   Schnyder Candrian, Silvia ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Allergy; Cytokines; Dendritic cells; IL 22; Lung inflammation

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22; OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EOSINOPHIL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; TH17 CELL;

ANIMALS; CELL MOVEMENT; DENDRITIC CELLS; EOSINOPHILS; HYPERSENSITIVITY; INTERLEUKIN-4; INTERLEUKINS; LYMPH NODES; MEDIASTINUM; MICE; MICE, INBRED BALB C; OVALBUMIN; SIGNAL TRANSDUCTION; TH1 CELLS; TH2 CELLS;

MUS;

EID: 77950860148     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.02.003     Document Type: Article

References (49)

1. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999, 17:255-281.
2. Schnyder-Candrian S., Togbe D., Couillin I., Mercier I., Brombacher F., Quesniaux V., et al. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006, 203:2715-2725.
3. Herrick C.A., Bottomly K. To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol 2003, 3:405-412.
4. Yang X.O., Chang S.H., Park H., Nurieva R., Shah B., Acero L., et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008, 205:1063-1075.
5. Linden A., Adachi M. Neutrophilic airway inflammation and IL-17. Allergy 2002, 57:769-775.
6. Michel M.L., Keller A.C., Paget C., Fujio M., Trottein F., Savage P.B., et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007, 204:995-1001.
7. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279.
8. Dumoutier L., Louahed J., Renauld J.C. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000, 164:1814-1819.
9. Renauld J.C. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 2003, 3:667-676.
10. Lejeune D., Dumoutier L., Constantinescu S., Kruijer W., Schuringa J.J., Renauld J.C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002, 277:33676-33682.
11. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Karow M., Flavell R.A. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007, 27:647-659.
12. Pan H., Hong F., Radaeva S., Gao B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 2004, 1:43-49.
13. Chang H., Hanawa H., Liu H., Yoshida T., Hayashi M., Watanabe R., et al. Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats. J Immunol 2006, 177:3635-3643.
14. Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118:534-544.
15. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005, 174:3695-3702.
16. Weber G.F., Gaertner F.C., Erl W., Janssen K.P., Blechert B., Holzmann B., et al. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 2006, 177:8266-8272.
17. Hofstetter H.H., Ibrahim S.M., Koczan D., Kruse N., Weishaupt A., Toyka K.V., et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol. 2005, 27:27.
18. Lubberts E., Schwarzenberger P., Huang W., Schurr J.R., Peschon J.J., Van den Berg W.B., et al. Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J Immunol 2005, 175:3360-3368.
19. Koenders M.I., Lubberts E., Oppers-Walgreen B., Van den Bersselaar L., Helsen M.M., Di Padova F.E., et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005, 167:141-149.
20. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
21. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
22. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651. [Epub 2006 Dec 24].
23. Andoh A., Zhang Z., Inatomi O., Fujino S., Deguchi Y., Araki Y., et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005, 129:969-984.
24. Ikeuchi H., Kuroiwa T., Hiramatsu N., Kaneko Y., Hiromura K., Ueki K., et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005, 52:1037-1046.
25. Di Stefano A., Caramori G., Gnemmi I., Contoli M., Vicari C., Capelli A., et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 2009, 157:316-324.
26. Koya T., Matsuda H., Takeda K., Matsubara S., Miyahara N., Balhorn A., et al. IL-10-treated dendritic cells decrease airway hyperresponsiveness and airway inflammation in mice. J Allergy Clin Immunol 2007, 119:1241-1250.
27. Hawrylowicz C.M., O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005, 5:271-283.
28. O'Garra A., Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004, 10:801-805.
29. Larche M. Regulatory T cells in allergy and asthma. Chest 2007, 132:1007-1014.
30. Grunig G., Warnock M., Wakil A.E., Venkayya R., Brombacher F., Rennick D.M., et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998, 282:2261-2263.
31. Van Oosterhout A.J., Fattah D., Van Ark I., Hofman G., Buckley T.L., Nijkamp F.P. Eosinophil infiltration precedes development of airway hyperreactivity and mucosal exudation after intranasal administration of interleukin-5 to mice. J Allergy Clin Immunol 1995, 96:104-112.
32. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
33. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
34. Liu Y.J., Soumelis V., Watanabe N., Ito T., Wang Y.H., Malefyt Rde W., et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol 2007, 25:193-219.
35. Schnyder-Candrian S., Quesniaux V.F., Di Padova F., Maillet I., Noulin N., Couillin I., et al. Dual effects of p38 MAPK on TNF-dependent bronchoconstriction and TNF-independent neutrophil recruitment in lipopolysaccharide-induced acute respiratory distress syndrome. J Immunol 2005, 175:262-269.
36. Palmqvist C., Wardlaw A.J., Bradding P. Chemokines and their receptors as potential targets for the treatment of asthma. Br J Pharmacol 2007, 151:725-736.
37. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006, 6:173-182.
38. Hellings P.W., Kasran A., Liu Z., Vandekerckhove P., Wuyts A., Overbergh L., et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003, 28:42-50.
39. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
40. Veldhoen M., Hirota K., Westendorf A.M., Buer J., Dumoutier L., Renauld J.C., et al. The aryl hydrocarbon receptor links T(H)17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 23:23.
41. Ye P., Rodriguez F.H., Kanaly S., Stocking K.L., Schurr J., Schwarzenberger P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001, 194:519-527.
42. Andoh A., Fujino S., Bamba S., Araki Y., Okuno T., Bamba T., et al. IL-17 selectively down-regulates TNF-alpha-induced RANTES gene expression in human colonic subepithelial myofibroblasts. J Immunol 2002, 169:1683-1687.
43. Silverman M.D., Zamora D.O., Pan Y., Texeira P.V., Baek S.H., Planck S.R., et al. Constitutive and inflammatory mediator-regulated fractalkine expression in human ocular tissues and cultured cells. Invest Ophthalmol Vis Sci 2003, 44:1608-1615.
44. Kanda N., Koike S., Watanabe S. IL-17 suppresses TNF-alpha-induced CCL27 production through induction of COX-2 in human keratinocytes. J Allergy Clin Immunol 2005, 116:1144-1150. [Epub 2005 Sep 26].
45. Schnyder B., Schnyder-Candrian S., Pansky A., Schmitz M.L., Heim M., Ryffel B., et al. IL-17 reduces TNF-induced Rantes and VCAM-1 expression. Cytokine 2005, 31:191-202.
46. Schnyder B., Lugli S., Feng N., Etter H., Lutz R.A., Ryffel B. Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. Blood 1996, 87:4286-4295.
47. Le Buanec H., Paturance S., Couillin I., Schnyder-Candrian S., Larcier P., Ryffel B., et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 2007, 25:7206-7216.
48. Desmet C., Gosset P., Pajak B., Cataldo D., Bentires-Alj M., Lekeux P., et al. Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol 2004, 173:5766-5775.
49. Fulkerson P.C., Zimmermann N., Hassman L.M., Finkelman F.D., Rothenberg M.E. Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma. J Immunol 2004, 173:7565-7574.